Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI LTS: Vedolizumab Long-term Safety in UC and CD
NCT00790933Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2009
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started May 2009; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT00790933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790933.